Decoding Leukemia: How NOTCH Activation Could Lead to Targeted Therapies
"Unlocking the role of glycosyltransferase expression in acute myeloid leukemia (AML) to revolutionize treatment approaches."
Acute myeloid leukemia (AML) is a complex and aggressive cancer affecting the bone marrow and blood. Scientists are constantly seeking new ways to understand and combat this disease. Recent research has shed light on the role of NOTCH signaling, a crucial pathway that regulates cell growth and differentiation, and its interaction with glycosylation, a process that modifies proteins with sugar molecules. This intersection could hold the key to developing more effective and targeted AML therapies.
NOTCH signaling plays diverse roles in regulating the growth of AML cells. Glycosylation of NOTCH receptors is known to modulate NOTCH activation. However, the specifics of NOTCH glycosylation in AML cells remain unclear. A new study has examined how ligand-induced NOTCH activation influences the expression of NOTCH-modifying glycosyltransferases, enzymes that control glycosylation, in AML cell lines.
Researchers stimulated AML cell lines, THP-1 and TMD7, with recombinant NOTCH ligands JAGGED1 and DELTA1, and then analyzed the expression levels of glycosyltransferases. The goal was to determine how NOTCH activation affects the glycosylation machinery within these cancer cells, potentially revealing new therapeutic targets.
AML Burden and NOTCH Relevance
The U.S. rate of new acute myeloid leukemia cases was 4.4 per 100,000 people per year, while the death rate was 2.7 per 100,000, based on age-adjusted data from 2019–2023 and 2020–2024, respectively. Research on NOTCH-1 mutations has examined their prevalence and clinical impact in AML, but the gene's role remains unclear. Separate findings reported that higher levels of NOTCH4 and Jagged2 were found in poor-cytogenetics-risk groups and associated with shorter survival. Together, these findings point to a clinically important but still unsettled relationship between NOTCH signaling and AML outcomes.
Current Care and Its Limits
AML care generally relies on established diagnostic, risk-assessment, monitoring, and treatment methods, but these approaches do not eliminate uncertainty for every patient. Outcomes can vary with disease biology and treatment response, making individualized decision-making important. The potential of NOTCH-directed treatment remains investigational, so it should not yet be presented as a standard replacement for accepted AML care.
From Pathway Biology to AML Research
NOTCH signaling was first understood as a developmental pathway involved in cell fate and blood formation before its relevance to blood cancers became a research focus. Subsequent studies connected NOTCH alterations with some leukemias, while its role in AML remained less settled. This history helps explain why current AML research continues to test whether NOTCH acts as a disease driver, suppressor, or context-dependent regulator.
Unveiling the Connection: NOTCH Signaling and Glycosyltransferase Expression
The study revealed that stimulating AML cells with NOTCH ligands significantly impacted the expression of several glycosyltransferases. In THP-1 cells, ligand stimulation boosted the expression of POFUT1, LFNG, MFNG, RFNG, GXYLT1, GXYLT2, and XXYLT1. In TMD7 cells, the expression of RFNG and GXYLT1 was increased.
- POFUT1: Essential for NOTCH activation by adding O-fucose moieties.
- LFNG, MFNG, RFNG: Fringe glycosyltransferases that add N-acetylglucosamine (GlcNAc) to O-fucose.
- GXYLT1, GXYLT2, XXYLT1: Involved in adding xylose residues, potentially inhibiting NOTCH activity.
Emerging NOTCH Strategies
A September 2024 study reported that NOTCH pathway inhibition, rather than activation, underlies acute megakaryoblastic leukemia leukemogenesis, suggesting that activating NOTCH could become a therapeutic strategy against AMKL. Recent AML reviews also describe major changes in diagnosis, risk assessment, monitoring, and management, including the addition of at least 12 approved therapies. The 2025 management review focuses on investigational treatments that might become standards of care in coming years. These sources present NOTCH activation as a promising but still research-stage idea within a rapidly changing AML treatment landscape.
Why the Evidence Remains Unsettled
The clinical role of NOTCH signaling in AML remains unclear because NOTCH pathway genes can function as oncogenes or tumor suppressors in different cancers. Research on AML has also described the contribution of NOTCH to leukemia-cell and bone-marrow-stromal-cell crosstalk as controversial. A 2022 analysis further reported that the clinical value of NOTCH mutations in AML is poorly defined, in contrast with their recognized importance and controversial impact in T-cell acute lymphoblastic leukemia. These limitations argue against assuming that one NOTCH-directed strategy will work across all AML settings.
Contrasting Views of NOTCH in AML
A 2022 review of NOTCH signaling in hematopoiesis and hematological neoplasia found both supportive and opposing views regarding NOTCH activity in AML. This contrast reflects the pathway's potentially context-dependent effects rather than a single, universally accepted role. The review specifically focuses on how conserved NOTCH signaling relates to AML and other blood cancers. Consequently, comparisons between studies should account for differences in disease context and the biological effect being measured.
The Future of AML Treatment: Targeting Glycosylation
This research opens new avenues for understanding and treating AML. By clarifying the relationship between NOTCH signaling and glycosyltransferase expression, scientists can explore novel therapeutic strategies that target glycosylation. Modulating NOTCH glycosylation could disrupt the signaling pathways that drive AML cell growth and survival, paving the way for more effective and less toxic treatments.
A Conditional Therapeutic Opportunity
The available evidence supports viewing NOTCH as a biologically important pathway whose therapeutic meaning in AML is not yet settled. Some research points toward NOTCH activation as a possible strategy in AMKL, while other findings associate NOTCH-related activity with adverse AML features. A cautious interpretation is therefore warranted: targeted therapy may depend on the specific leukemia subtype, cellular context, and signaling state.
Testing the Next Strategies
Future research will need to determine when NOTCH activation or inhibition is biologically appropriate in AML. Progress will likely depend on better definition of disease subgroups, treatment responses, and the relationship between leukemia cells and their surrounding marrow environment. Until those questions are resolved, NOTCH-directed approaches remain promising possibilities rather than established therapies.
Complex Biology, Complex Care
AML research must connect molecular findings with diagnosis, risk assessment, monitoring, and treatment decisions. The unsettled evidence surrounding NOTCH illustrates the broader challenge of translating pathway biology into dependable clinical benefit. Effective progress will require integrating disease heterogeneity, treatment evaluation, and real-world care constraints rather than relying on a single molecular signal.
Uncertain Prognosis, Ongoing Investigation
NOTCH signaling is involved in normal and malignant blood formation, but its role in AML remains under investigation and has produced controversial results. This uncertainty matters to patients because a pathway that appears promising in laboratory or subgroup research may not yet predict benefit from a targeted treatment. For now, NOTCH findings should be interpreted as part of an evolving prognostic and therapeutic research field, not as a definitive guide for individual care.